ivacaftor
Jump to navigation
Jump to search
Indications
- cystic fibrosis patients with at least 1 CFTR mutation G551D
- used in combination with lumacaftor for treatment of cystic fibrosis CFTR F508del mutation[2]
Dosage
- 150 mg PO every 12 hours
Mechanism of action
- CFTR potentiator
More general terms
Component of
References
- ↑ Ramsey BW et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011 Nov 3; 365:1663. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22047557
Davis PB. Therapy for cystic fibrosis - The end of the beginning? N Engl J Med 2011 Nov 3; 365:1734. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22047565 - ↑ 2.0 2.1 FDA News Release. July 2, 2015 FDA approves new treatment for cystic fibrosis http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm453565.htm